---
title: Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune
  checkpoint inhibition and targeted therapy in patients with advanced melanoma
date: '2024-03-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38484692/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240315180616&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Triplet therapy has shown activity in heavily pretreated
  patients with advanced melanoma and may represent a potential treatment regimen
  after failure of ICI and ...'
disable_comments: true
---
CONCLUSIONS: Triplet therapy has shown activity in heavily pretreated patients with advanced melanoma and may represent a potential treatment regimen after failure of ICI and ...